A first-in-class therapy for intestinal malabsorption in premature newbornsbroad
ELGN-GI · Horizon Europe grant · 2022-11-01–2024-10-31
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2022-ACCELERATOR-01 · scheme HORIZON-EIC-ACC-BF · topic HORIZON-EIC-2022-ACCELERATORCHALLENGES-01. CORDIS record →
Objective
Around 10% babies are born preterm, and premature birth is the 1st cause of new-born deaths. Preterm infants are born with an underdeveloped gastrointestinal (GI) tract, causing intestinal malabsorption. At the first weeks of life, adequate nutrition is critical for brain and vital organ development, so infants are placed on central line nutrition until their GI is capable of absorbing sufficient nutrition. However, central line nutrition is inadequate for critical growth and poses life-threatening risks. Thus, a fast transition to oral independence is the goal for improving outcomes. ELGN-GI is the first drug for stimulating gut maturation for rapid transition to oral nutrition. It is safe and demonstrated to reduce 4 days dependent on Parenteral Nutrition, ~7 days in high-level NICU, ~7 days in hospitalization period, and to contribute to 40% reduction of life-threatening infections and Necrotizing Enterocolitis.
Beneficiaries (1)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| ELGAN PHARMA LTD. | IL | coordinator | €2,359,000 | Yes |
Get the EU Defence Funding Calendar — free
The full calendar of open EU defence and dual-use funding calls, sorted by deadline, updated nightly. Delivered with DFM Analysis, our weekly briefing on who is funding what in European defence.
Or browse all open defence & dual-use calls on the funding calendar →
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; the paid Annual Professional subscription is handled on DFM Analysis.